Citations (23)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Ankit Shah & Jacqueline C Barrientos. (2021) Oral PI3K-δ,γ Inhibitor for the Management of People with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: A Narrative Review on Duvelisib. OncoTargets and Therapy 14, pages 2109-2119.
Read now
Read now
Henriette Huber, Simone Edenhofer, Sven Estenfelder & Stephan Stilgenbauer. (2017) Profile of venetoclax and its potential in the context of treatment of relapsed or refractory chronic lymphocytic leukemia. OncoTargets and Therapy 10, pages 645-656.
Read now
Read now
Heike Horn, Annette M. Staiger & German Ott. (2017) New targeted therapies for malignant lymphoma based on molecular heterogeneity. Expert Review of Hematology 10:1, pages 39-51.
Read now
Read now
Articles from other publishers (20)
Miaomiao Yu, Jiajia Chen, Zhifei Xu, Bo Yang, Qiaojun He, Peihua Luo, Hao Yan & Xiaochun Yang. (2023) Development and safety of PI3K inhibitors in cancer. Archives of Toxicology 97:3, pages 635-650.
Crossref
Crossref
Taylor M Weis, Jillian Gutierrez, Charlene C Kabel, Amber C King, Ryan J Daley & Sarah E Stump. (2022) Real-world management of targeted therapies in chronic lymphocytic leukemia. Journal of Oncology Pharmacy Practice 28:6, pages 1411-1433.
Crossref
Crossref
Pritha Shah, Aqsa Siddique, Ami Thakkar, Sankalp Gharat, Angel Godad, Pravin Kale & Gaurav Doshi. (2022) An update on novel therapeutic intervention in Rheumatoid arthritis. International Immunopharmacology 109, pages 108794.
Crossref
Crossref
Mario Fernández-Ruiz. 2022. Infectious Complications in Biologic and Targeted Therapies. Infectious Complications in Biologic and Targeted Therapies
3
15
.
María N. Barrachina, Irene Izquierdo, Lidia Hermida-Nogueira, Luis A. Morán, Amparo Pérez, Ana B. Arroyo, Nuria García-Barberá, Rocío González-Conejero, Sara Troitiño, Johannes A. Eble, José Rivera, Constantino Martínez, María I. Loza, Eduardo Domínguez & Ángel García. (2021) The PI3Kδ Inhibitor Idelalisib Diminishes Platelet Function and Shows Antithrombotic Potential. International Journal of Molecular Sciences 22:7, pages 3304.
Crossref
Crossref
Tycel J. Phillips, Jean-Marie Michot & Vincent Ribrag. (2021) Can Next-Generation PI3K Inhibitors Unlock the Full Potential of the Class in Patients With B-Cell Lymphoma?. Clinical Lymphoma Myeloma and Leukemia 21:1, pages 8-20.e3.
Crossref
Crossref
Elisabeth Foki, Isabella Stanisz, Lorenz Kadletz, Ulana Kotowski, Rudolf Seemann, Rainer Schmid & Gregor Heiduschka. (2020) HS-173, a selective PI3K inhibitor, induces cell death in head and neck squamous cell carcinoma cell lines. Wiener klinische Wochenschrift 133:1-2, pages 26-31.
Crossref
Crossref
Rifat Mannan, Kevin M. Waters & Elizabeth Montgomery. 2021. Practical Gastrointestinal Pathology. Practical Gastrointestinal Pathology
267
287
.
Valentina Giudice, Carmine Vecchione & Carmine Selleri. (2020) Cardiotoxicity of Novel Targeted Hematological Therapies. Life 10:12, pages 344.
Crossref
Crossref
Salma Machan, Carlos Plaza, Yosmar Pérez-González, Maria Rodriguez-Pinilla, Luis Requena & Raul Cordoba. (2020) Management of psoriasis-like rash associated with idelalisib monotherapy in a patient with refractory follicular lymphoma: a case report. Journal of Medical Case Reports 14:1.
Crossref
Crossref
Lei Fan, Chao Wang, Liwen Zhao, Zhiqiang Wang, Xian Zhang, Xiaorong Liu, Lei Cao, Wei Xu & Jianyong Li. (2020) SHC014748M, a novel selective inhi-bitor of PI3Kδ, demonstrates promising preclinical antitumor activity in B cell lymphomas and chronic lymphocytic leukemia. Neoplasia 22:12, pages 714-724.
Crossref
Crossref
Annika ScheffoldBilly Michael Chelliah JebarajEugen TauschJohannes BloehdornPaolo Ghia, Anella YahiaouiAnna DolnikTamara Jacqueline BlätteLars BullingerRashmi Priyadharshini DheenadayalanLi LiChristof SchneiderShih-Shih Chen, Nicholas Chiorazzi, Sascha DietrichMartina Seiffert, Stacey TannheimerHartmut DöhnerDaniel Mertens & Stephan Stilgenbauer. (2019) IGF1R as druggable target mediating PI3K-δ inhibitor resistance in a murine model of chronic lymphocytic leukemia. Blood 134:6, pages 534-547.
Crossref
Crossref
Stefania Crisci, Filomena Amitrano, Mariangela Saggese, Tommaso Muto, Sabrina Sarno, Sara Mele, Pasquale Vitale, Giuseppina Ronga, Massimiliano Berretta & Raffaele Di Francia. (2019) Overview of Current Targeted Anti-Cancer Drugs for Therapy in Onco-Hematology. Medicina 55:8, pages 414.
Crossref
Crossref
Dan Yue & Xun Sun. (2018) Idelalisib promotes Bim-dependent apoptosis through AKT/FoxO3a in hepatocellular carcinoma. Cell Death & Disease 9:10.
Crossref
Crossref
Julieta Sepulveda, Noé Seija, Pablo Oppezzo & Marcelo A. Navarrete. 2018. Hematology - Latest Research and Clinical Advances. Hematology - Latest Research and Clinical Advances.
M. Fernández-Ruiz, Y. Meije, O. Manuel, H. Akan, J. Carratalà, J.M. Aguado & J. Delaloye. (2018) ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Introduction). Clinical Microbiology and Infection 24, pages S2-S9.
Crossref
Crossref
Miriam Marangon, Cinzia Pellegrini, Lisa Argnani & Pier Luigi Zinzani. (2018) Efficacy of Idelalisib as Bridge to Allogeneic Stem Cell Transplant in Relapsed Follicular Lymphoma: A Case Report. Tumori Journal 103:1_suppl, pages S41-S43.
Crossref
Crossref
Tommy Tsang Cheung & Iain B. McInnes. (2017) Future therapeutic targets in rheumatoid arthritis?. Seminars in Immunopathology 39:4, pages 487-500.
Crossref
Crossref
Michael Vieth & Elizabeth Montgomery. (2017) Medication-associated gastrointestinal tract injury. Virchows Archiv 470:3, pages 245-266.
Crossref
Crossref
Ifeyinwa E Obiorah, Lynt Johnson & Metin Ozdemirli. (2017) Primary mucosa-associated lymphoid tissue lymphoma of the liver: A report of two cases and review of the literature. World Journal of Hepatology 9:3, pages 155.
Crossref
Crossref